ISSN 2756-3251
Advanced Journal of Environmental Science and Technology ISSN 2756-3251 Vol. 11 (6), pp. 001-005, June, 2020. © International Scholars Journals
Full Length Research Paper
Lavudine therapy and hepatotoxicity as seen in a Nigerian tertiary antiretroviral treatment centre
Akande A. A1*, Olaosebikan O. F1, Jimoh A. K1, Abdulazeez1, 2Olawumi H. O
1Department of Chemical Pathology and Immunology, University of Ilorin Teaching Hospital, PMB 1459, Ilorin, Kwara State, Nigeria.
2Department of Hematology and Blood transfusion Services, University of Ilorin Teaching Hospital, PMB 1459, Ilorin, Kwara State, Nigeria.
Accepted 18 April, 2020
Abstract
Hepatic toxicity is a common complication of anti-retroviral treatment in HIV patients, usually indicated or heralded by the elevation of liver transaminases measured in the blood. There had been reported evidence of hepatic toxicity in all the three currently approved classes of anti-retroviral drugs. However, its severity in some cases may warrant stoppage of the treatment. This study assessed the hepato-toxicity among HIV patients on antiretroviral therapy with lavudine in a drug treatment centre in Nigeria. Liver function test (LFT) results of patients treated with lavudine (lamivudne, stavudine and nevirapine) antiretroviral drug was collated and analyzed initially as baseline data and later over a period of three months after treatment with lavudine for liver enzymes assessment. Sixty three (63) subjects in all were analyzed, 28 males and 35 females (M: F = 0.8:1) . The results showed that there was a non-significant (p>0.45) decrease in the serum transaminases and alkaline phosphatase of the pretreatment LFT compared with the LFT after three months of treatment with lavudine. The levels of serum total protein and albumin showed a concomitant but non-significant (p>0.20) decrease over the same period. Antiretroviral treatment with lavudine may be associated with hepatic enzymes induction but not toxicity at least in the short run, however hepatic function test should be monitored every month for the first three months after starting a new drug regimen and followed by once in six month subsequently for a year.
Key words: Lavudine, hepatotoxicity, treatment centre, HIV /AIDS patient.